Celltrion, KR7068270008

Celltrion stock: Herzuma wins seven-year Brazil tender extension

Published on 11/17/2026 at 04:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Celltrion won a Brazilian federal tender for about 1 million Herzuma vials through 2027. Celltrion stock faces a broader biosimilar growth outlook.

Brazil Tender Strengthens Celltrion

  • Celltrion will supply about 1 million Herzuma vials to Brazil through the end of 2027.
  • The award extends Herzuma's run of successful Brazilian federal tenders to seven consecutive years.
  • Celltrion is preparing additional launches in Brazil, including Idenselt and Aptozma.
Celltrion, KR7068270008, Illustration mit AI erstellt.

Celltrion won a Brazilian federal government tender for its Herzuma breast and stomach cancer treatment on November 17, extending the product's run of successful awards in the country to seven consecutive years. The company said its Brazilian unit will supply about 1 million vials exclusively through the end of 2027.

The award covers a tender that represents about 80 percent of Brazil's public trastuzumab market, according to a Celltrion press release. Celltrion said its local direct-sales strategy, relationships with public-sector stakeholders and supply capacity supported the win.

Brazil Expands Biosimilar Opportunity

Herzuma holds about 50 percent of Brazil's market based on IQVIA data, making it the leading prescribed product in the category. Celltrion expects the tender to support further growth in Brazil next year while it expands its product portfolio across Latin America.

The company also plans to build sales of Omlyclo, its omalizumab treatment for chronic spontaneous urticaria. Idenselt, an aflibercept ophthalmic treatment, and Aptozma, a tocilizumab autoimmune treatment, are targeted for launch in Brazil by the end of the year.

Celltrion's Business And Market Position

Celltrion develops and sells biologic medicines, with biosimilars forming a central part of its international product portfolio. Its products address oncology, autoimmune, allergy and ophthalmic conditions across markets including Brazil, the United States and Europe. The company combines product development, manufacturing capacity and local commercial operations to supply healthcare systems and private providers.

Celltrion Company Facts

  • Company: Celltrion Inc.
  • ISIN: KR7068270008
  • Focus: Biologic medicines and biosimilars
  • Key product in this report: Herzuma
  • Announcement date: November 17, 2026

South Korean healthcare shares can be followed in the KOSPI market environment.

More news and analyses on Celltrion stock are available here.

Disclaimer...
en | KR7068270008 | CELLTRION | boerse | 70524132 | bgmi